NASDAQ:APGE

Apogee Therapeutics Q2 2026 Earnings Results & Report

Apogee Therapeutics logo

Apogee Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$1.14 versus the -$1.07 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Apogee Therapeutics EPS Results

Actual EPS
-$1.14
Consensus EPS
-$1.07
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Apogee Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apogee Therapeutics Q2 2026 Earnings FAQ

Apogee Therapeutics (NASDAQ:APGE) reported earnings of -$1.14 per share for Q2 2026, missing the consensus estimate of -$1.07. The report was announced on Monday, August 10, 2026.

Apogee Therapeutics Earnings Headlines

The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Apogee Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email.

About Apogee Therapeutics

Apogee Therapeutics (NASDAQ:APGE), Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic medicines for inflammatory and immunologic diseases. The company’s approach emphasizes therapies designed to offer extended dosing intervals, with the goal of improving convenience and treatment options for patients with chronic conditions.

Apogee’s lead program is APG777, a long-acting monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in allergic inflammation. The program is being developed for conditions including atopic dermatitis, asthma and other inflammatory diseases. The company is also advancing APG808, an extended-half-life antibody targeting the interleukin-4 receptor alpha (IL-4Rα) pathway, which is implicated in several type 2 inflammatory disorders.

Apogee was established in 2022 and became a publicly traded company on the Nasdaq under the symbol APGE in 2023. The company is headquartered in San Francisco, California, and its development activities are focused on addressing unmet needs in inflammatory and immunologic diseases. Apogee is led by Chief Executive Officer Michael Henderson.

View Apogee Therapeutics Profile